Suppr超能文献

小容量复苏用 20%白蛋白在重症监护中:生理效应:SWIPE 随机临床试验。

Small volume resuscitation with 20% albumin in intensive care: physiological effects : The SWIPE randomised clinical trial.

机构信息

Department of Intensive Care, Austin Hospital, Melbourne, Australia.

Department of Physiology and Pharmacology, Section of Anaesthesia and Intensive Care, Karolinska Institutet, Stockholm, Sweden.

出版信息

Intensive Care Med. 2018 Nov;44(11):1797-1806. doi: 10.1007/s00134-018-5253-2. Epub 2018 Oct 21.

Abstract

PURPOSE

We set out to assess the resuscitation fluid requirements and physiological and clinical responses of intensive care unit (ICU) patients resuscitated with 20% albumin versus 4-5% albumin.

METHODS

We performed a randomised controlled trial in 321 adult patients requiring fluid resuscitation within 48 h of admission to three ICUs in Australia and the UK.

RESULTS

The cumulative volume of resuscitation fluid at 48 h (primary outcome) was lower in the 20% albumin group than in the 4-5% albumin group [median difference - 600 ml, 95% confidence interval (CI) - 800 to - 400; P < 0.001]. The 20% albumin group had lower cumulative fluid balance at 48 h (mean difference - 576 ml, 95% CI - 1033 to - 119; P = 0.01). Peak albumin levels were higher but sodium and chloride levels lower in the 20% albumin group. Median (interquartile range) duration of mechanical ventilation was 12.0 h (7.6, 33.1) in the 20% albumin group and 15.3 h (7.7, 58.1) in the 4-5% albumin group (P = 0.13); the proportion of patients commenced on renal replacement therapy after randomization was 3.3% and 4.2% (P = 0.67), respectively, and the proportion discharged alive from ICU was 97.4% and 91.1% (P = 0.02).

CONCLUSIONS

Resuscitation with 20% albumin decreased resuscitation fluid requirements, minimized positive early fluid balance and was not associated with any evidence of harm compared with 4-5% albumin. These findings support the safety of further exploration of resuscitation with 20% albumin in larger randomised trials.

TRIAL REGISTRATION

http://www.anzctr.org.au . Identifier ACTRN12615000349549.

摘要

目的

我们旨在评估在重症监护病房(ICU)患者中使用 20%白蛋白和 4-5%白蛋白进行复苏时的复苏液需求以及生理和临床反应。

方法

我们在澳大利亚和英国的 3 个 ICU 中,对 321 名在入院后 48 小时内需要液体复苏的成年患者进行了一项随机对照试验。

结果

在 48 小时时(主要结局),20%白蛋白组的复苏液累积量低于 4-5%白蛋白组[中位数差值-600ml,95%置信区间(CI)-800 至-400;P<0.001]。20%白蛋白组在 48 小时时的累积液体平衡量较低[平均差值-576ml,95%CI-1033 至-119;P=0.01]。20%白蛋白组的白蛋白峰值较高,但钠和氯水平较低。20%白蛋白组机械通气的中位(四分位间距)时间为 12.0 小时(7.6,33.1),4-5%白蛋白组为 15.3 小时(7.7,58.1)(P=0.13);随机分组后开始接受肾脏替代治疗的患者比例分别为 3.3%和 4.2%(P=0.67),从 ICU 出院存活的患者比例分别为 97.4%和 91.1%(P=0.02)。

结论

与 4-5%白蛋白相比,使用 20%白蛋白复苏可减少复苏液需求,最大限度地减少早期正性液体平衡,且没有任何证据表明存在危害。这些发现支持在更大规模的随机试验中进一步探索使用 20%白蛋白复苏的安全性。

试验注册

http://www.anzctr.org.au。标识符 ACTRN12615000349549。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验